

Alloimmunity & Trauma

Team Pham

08 November, 2018

Contents

Table 1: Demographics	1
Table 2: Antibody characteristics	1
Table 3: Transfusion and Antibody Development	1
Table 4: Outcomes analysis	1
Table 2: Antibody characteristics	1

Table 1: Demographics

	Anti- (3947)	Anti+ (185)	p^a
Age (years) (mean (sd))	47.33 (19.15)	50.39 (19.93)	0.034
Gender (% male)	2814 (71.3)	121 (65.4)	0.100
Ethnicity (% African American)	2773 (70.3)	130 (70.3)	1.000
Mortality (%)	447 (11.3)	39 (21.1)	<0.001
Length of admission (median [IQR])	11.58 [5.96, 22.13]	30.72 [16.45, 53.43]	<0.001
Number of RBC transfusion (median [IQR])	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	<0.001
Number of Type & Screen tests performed (median [IQR])	1.00 [0.00, 2.00]	3.00 [1.00, 7.00]	<0.001

	Anti- (3947)	Anti+ (185)	p^a
Age (years) (mean (sd))	47.33 (19.15)	50.39 (19.93)	0.034
Gender (% male)	2814 (71.3)	121 (65.4)	0.100
Ethnicity (% African American)	2773 (70.3)	130 (70.3)	1.000
Mortality (%)	447 (11.3)	39 (21.1)	<0.001
Length of admission (median [IQR])	11.58 [5.96, 22.13]	30.72 [16.45, 53.43]	<0.001
Number of RBC transfusion (mean (sd))	0.14 (1.02)	1.75 (7.23)	<0.001
Number of Type & Screen tests performed (median [IQR])	1.00 [0.00, 2.00]	3.00 [1.00, 7.00]	<0.001

Table 2: Antibody characteristics

Table 3: Transfusion and Antibody Development

Table 4: Outcomes analysis

Table 2: Antibody characteristics